Neovasc Provides Update on German Litigation
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”)
(NASDAQ, TSX: NVCN) reported today that the Higher Regional
Court in Munich, Germany has upheld the first instance
judgment of the Regional Court Munich of June 16, 2017, in which
the court had found that Edwards Lifesciences LLC ("Edwards") had
contributed in part to the invention of the Tiara™ and awarded to
Edwards co-entitlement rights to the disputed Tiara™ European
patent application. There are no monetary awards associated with
these matters and no damages award was recognized.
Neovasc is currently reviewing its possibilities for appeal.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara™ for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to, the
Company’s review of its possibilities for appeal
and expectations as to the growing cardiovascular marketplace.
Forward-looking statements are based on estimates and assumptions
made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors could
cause the Company's actual results, performance or achievements to
differ materially from those expressed or implied by
the forward looking statements, including those described
in the "Risk Factors" section of the Company's Annual Information
Form and in the Management's Discussion and Analysis for the three
months ended March 31, 2021 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Historical Stock Chart
From Aug 2021 to Sep 2021
Historical Stock Chart
From Sep 2020 to Sep 2021